Issuu on Google+

FOR MORE INFORMATION: American CryoStem 732-747-1007 or via email at info@americancryostem.com

 

AMERICAN CRYOSTEM 2016 YEAR END UPDATE EATONTOWN, NJ / ACCESSWIRE / January 4, 2017 / American CryoStem Corporation (CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released Summary corporate and financial highlight information regarding the Company’s year ending September 30, 2016; •   The Company's Total Revenue increased 75% in Fiscal 2016 versus 2015 •   Contributing to the Total Revenue increase for Fiscal 2016, International Revenue increased 19% in Fiscal 2016 versus Fiscal 2015 •   Accounts Receivable increased 15% in Fiscal 2016 versus Fiscal 2015 •   Tissue storage and processing increased 289% in Fiscal 2016 versus Fiscal 2015 •   Research & Development decreased 60% in Fiscal 2016 compared to Fiscal 2015 which is attributed to; the completion of certain research projects •   Professional fees increased (principally legal and accounting) 130% in Fiscal 2016 compared to Fiscal 2015 due to an increase in legal expenses for the prosecution of our international patent portfolio, and optimization and scale up work associated with the licensing of our patented cell culture media, ACSelerate Max, to PeproTech in 2016 “American CryoStem’s 2016 results reflect an increased interest by the medical and patient populations to seek out natural cosmetic solutions and products, and cellular therapies as alternative treatments for those that are not responding to traditional treatment solutions. We believe that we are well positioned to respond to these increased interests and look forward to continuing our year over year positive results” stated Anthony Dudzinski, COO. John S. Arnone, CEO stated, “We are very optimistic about the state of the Regenerative Medicine Industry in the United States and globally as we enter 2017. We have seen a steady increase of new patients storing their stem cells for future use and physicians utilizing our products and service in 2016. We are in discussions for new global territories with licensees seeking to establish our adipose tissue (fat) based collect-process-store, stem cell platform in their country”. This increased interest in cellular therapies is evidenced in eight thousand (8,000+) plus clinical trials currently registered with ClinicalTrials.gov focused on adipose tissue and its derivatives which include; adipose tissue (2,083), adult stem cells (5,709), adipose derived stem cells, mesenchymal stem cells and stromal vascular fraction (SVF). Arnone further stated, “In 2017 we look forward to expanding our US based physician network, patient stem cell storages and increasing our global laboratory footprint as regenerative and personalized medicine applications become main stream”.


In 2017 management intends to continue its focus on increasing revenue, reducing costs and plans to begin a comprehensive investor and customer relations programs in Fiscal 2017. About American CryoStem Corporation American CryoStem Corporation (OTCQB: CRYO); was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary, IRB approved, FDA compliant platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physicians networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC’s) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company’s R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.

For further detailed corporate or Regenerative Medicine information please visit: www.americancryostem.com, request by email at info@americancryostem.com or phone 732-747-1007

This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.


American CryoStem 2016 Year End Update